Identification of Autoantibodies and Autoantigens in the Cerebrospinal Fluid of Patients With Spinal Cord Trauma

University Hospital, Lille

Overview

The purpose of the study is to detect the presence of autoantibodies and autoantigens in cerebrospinal fluid early (\<48 hours) following spinal cord trauma. The study also aims to define the central or peripheral origin of autoantibodies by looking for their simultaneous presence at the blood level and to evaluate the prognostic value of the presence of autoantibodies within the cerebrospinal fluid, as well as on the initial clinical severity than on the recovery potential.

Study Type

OBSERVATIONAL

Conditions

Bone Marrow Failure Trauma

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Patients with spinal cord injury dating back less than 48 hours 2. Men or women over 18 years of age 3. Patients benefiting from social protection 4. Surgery performed within 48 hours of the trauma 5. Informed and signed consent by the patient or trusted person Exclusion Criteria: 1. Contra-indication to ensure surgical decompression within the first 48 hours following the trauma 2. Coagulation disorders or any condition that may make the lumbar puncture risky (eg, history of lumbar surgery) 3. Severe cranial trauma associated 4. History of autoimmune pathology 5. Immunosuppressive therapy or long-term corticosteroid therapy 6. Patients unable to comply with protocol requirements 7. Person benefiting from legal protection (guardianship / curator) 8. Person deprived of liberty 9. Patient unable to express consent 10. Pregnant women

Outcomes

Primary Outcomes

Level of anti glial fibrillary acid protein antibodies

Anti glial fibrillary acid protein antibodies measured into the cerebrospinal fluid

Time frame: The sampling is performed at the initial stage, i.e. within 48 hours after trauma. The time between trauma and sampling is specified and measured in hours.

Secondary Outcomes

Blood level of anti glial fibrillary acid protein antibodies

Anti glial fibrillary acid protein antibodies measured into the blood

Time frame: The sampling is performed at the initial stage, i.e. within 48 hours after trauma. The time between trauma and sampling is specified and measured in hours.

Severity of Neurological Impairment

Measured using the American Society Injury Association score

Time frame: in the initial phase, at day 7, at 1 months, 3 months, 6 months and 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.